Altre lingue Moleculin Biotech, Inc.

Azioni

MBRX

US60855D3098

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 28/06/2024			Variaz. 5gg	Var. 1 gen.
3,52 ^USD	0,00%		-5,88%	-72,66%

14/06	Moleculin Biotech, Inc. annuncia ulteriori dati preliminari positivi ad interim dello studio clinico AML	CI
15/05	Moleculin annuncia l'inizio dello studio clinico di Fase 2 finanziato dal NIH sull'inibitore di STAT3 per il trattamento del glioblastoma (Nu 21C06)	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial	14/06
Moleculin Biotech, Inc. Announces Additional Positive Preliminary Interim Data from AML Clinical Trial	14/06
Moleculin to Present at the Virtual Investor Pitch Conference	12/06
Moleculin to Participate in the Virtual Investor Lunch Break Series	05/06
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma	16/05
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress	16/05
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)	15/05
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (Nu 21C06)	15/05
Moleculin Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin	09/05
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast	08/05
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data	07/05
Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data	07/05
Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024	03/05
Moleculin Biotech, Inc. Announces Formation of Annamycin Scientific Advisory Board and Inaugural Appointment of Martin Tallman	01/05
European Medicines Agency Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia	19/04
Sector Update: Health Care Stocks Ease in Afternoon Trading	18/04
Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU	18/04
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)	18/04
Top Premarket Decliners	16/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Moleculin Biotech, Inc.

Azioni

MBRX

US60855D3098

Altre lingue

Filtri